Overall Technical outlook

Price Summary

Glenmark Pharmaceuticals Limited's stock, on 2026-02-27 opened at 2125.6, climbed to a high of 2159.8, dropped to a low of 2116.4, and closed up 0.52% at 2136.7, with 616208 shares traded.
Over the past 52 weeks, the stock reached a maximum price of 2226.7 and a minimum price of 0.0.
The future price of GLENMARK is anticipated to range from 1500.0 to 2735.0, with an expected mean price of 2192.6667, according to the recommendations of 12 analysts.

Technicals


Aroon: The bullish trend in Aroon remains, with Aroon Up consistently at the 100 level. This points to sustained upward momentum, but the trend should be explored further alongside other indicators to better understand its implications.
GLENMARK aroon e2af40
Aroon chart for Glenmark Pharmaceuticals Limited


Bol. Bands: The current price for GLENMARK has recently crossed above the upper Bollinger Band, signaling a strong bullish move. This breakout indicates that buying pressure is pushing prices higher than the usual range, often seen as a sign of increased momentum. Such a move may suggest that the market is experiencing heightened optimism, potentially leading to further upward price action.
GLENMARK bbands e2af40
Bolinger Bands chart for Glenmark Pharmaceuticals Limited


Parabolic SAR: The PSAR continues to indicate a bullish outlook, setting a crucial support level. This strong support could bolster the ongoing upward trend, suggesting that the market may remain in a positive trajectory. Investors may view this as a sign of sustained bullish momentum.
GLENMARK psar e2af40
Parabolic Stop and Reverse chart for Glenmark Pharmaceuticals Limited


Stochastic: The stochastic indicator reflects bullish conditions for GLENMARK, with the K-line above both the D-line and the 80 level. This setup suggests strong upward momentum, implying that the market may continue to experience gains. Investors could interpret this as a sign of ongoing strength.
GLENMARK stoch e2af40
Stochastic chart for Glenmark Pharmaceuticals Limited


Tripple Moving Agerage: The Tripple MOVING AVG is showing a neutral stance, with no definitive indication of an upward or downward trend for GLENMARK. This neutral position suggests a period of indecision in the market, making it difficult to predict the next move.
GLENMARK trippleSMA e2af40
Tripple SMA chart for Glenmark Pharmaceuticals Limited


To accurately interpret a company's technical data, it is important to first examine its fundamentals. These include financial performance, management quality, and growth prospects. In addition, understanding the dynamics of the industry in which the company operates—such as competition, market trends, and regulatory factors—provides further insights. This combined analysis helps create a fuller picture, allowing for more precise conclusions to be drawn from the company's technical performance and stock behavior.